Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11326166 Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

Patent 11326166 was granted and assigned to Alnylam Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the xanthine dehydrogenase (XDH) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an XDH gene and to methods of treating or preventing an XDH-associated disease in a subject.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11326166 Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo